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Klebsiella pneumoniae (K.pneumoniae) is a common nosocomial pathogen
causing bloodstream infections. Antibiotic susceptibility surveillance and molecular
characterization will facilitate prevention and management of K. pneumoniae
bloodstream infections. K. pneumoniae isolates causing bloodstream infections
were consecutively collected between January 2012 and December 2015 in Shanghai.
Eighty isolates (20 per year) were randomly selected and enrolled in this study.
Drug susceptibility were determined by the disk diffusion method. Polymerase chain
reaction (PCR) was employed to detect extended-spectrum β-lactamases (ESBLs),
carbapenemases, and seven housekeeping genes of K. pneumoniae. eBURST was
used for multi-locus sequence typing (MLST). More than 50% isolates were resistant
to cefuroxime, ampicillin-sulbactam, and piperacillin, while carbapenems had lower
resistant rates than other antibiotics. Of the 80 isolates, 22 produced ESBLs, and
14 were carbapenemase producers. In the ESBL-producing K. pneumoniae isolates,
the most common ESBL genes were blaSHV and blaCTX−M. Thirteen carbapenemase
producers harbored blaKPC−2 and one other carried blaNDM−5. ST11 (14/80) was the
most frequent sequence type (ST), followed by ST15 (7/80) and ST29 (4/80). Our data
revealed high prevalence of antibiotic resistant K. pneumoniae isolates from bloodstream
infections but their genetic diversity suggested no clonal dissemination in the region.
Also, one K. pneumoniae isolate harbored blaNDM−5 in this study, which was firstly
reported in Shanghai.
Keywords: Klebsiella pneumoniae, bloodstream infections, resistance phenotype, molecular epidemiology,
extended-spectrum β-lactamase
Xiao et al. Klebsiella Pneumoniae in Bloodstream Infections
INTRODUCTION
Klebsiella pneumoniae (K. pneumoniae) can cause ventilator-
associated pneumonia, urinary tract infection, sepsis, catheter-
related infection, and bacterial meningitis (Tumbarello et al.,
2006; Du et al., 2014), and is also the most common causative
gram-negative bacterium in nosocomial and community-
acquired infections (Hu et al., 2015). Unfortunately, extended
and overuse of antibiotics may potentiate antibiotic resistance
of K. pneumoniae strains to cephalosporins, aminoglycosides,
fluoroquinolones, and even carbapenems (Guana et al., 2014),
which will be difficult and costly to control.
Extensive use of invasive procedures and glucocorticoids has
increased the incidence of bloodstream infections and caused
high mortality in patients (27.2–40.8%; Marra et al., 2006; Yang
et al., 2010; Lv et al., 2014; Wang et al., 2016). Of the gram
negative bacilli implicated in nosocomial bloodstream infections,
K. pneumoniae was one of the most common pathogens, second
only to Escherichia coli (Ghadiri et al., 2012; Lv et al., 2014). The
prevalence of Klebsiella spp. bloodstream infections was 7.6% in
the United States, Canada, South America, and Europe according
to SENTRY (Biedenbach et al., 2004). On the basis of a large-
scale survey from China, K. pneumoniae caused 11.3% of all
bloodstream infections in 2011–2012 (Lv et al., 2014).
The wide dissemination of drug resistant pathogens leads
to their increasing prevalence in bloodstream infections. Data
from China showed that 53.3% K. pneumoniae isolates were
multidrug-resistant (Lv et al., 2014). In Europe, Latin America,
and North America, 21.7, 42.7, and 5.8% of Klebsiella spp. had the
extended-spectrum β-lactamase (ESBL) phenotype (Biedenbach
et al., 2004), while as high as 60.6% K. pneumoniae isolates in
Greece were carbapenemase producers (Daikos et al., 2014). And
the most prevalent group of carbapenemases was K. pneumonia
carbapenemase (KPC). Studies have shown that the drug-
resistant organisms bloodstream infection was one important
risk factor for mortality and negatively impacted the treatment
outcome of patients (Kim et al., 2002; Tumbarello et al., 2006).
Limited data on susceptibility and molecular epidemiology of
K. pneumoniae causing bloodstream infections were available in
Shanghai. In the study, we have monitored resistance phenotype,
the prevalent resistant genes and sequence types (STs) of K.
pneumoniae isolates from bloodstream infections between 2012
and 2015 in the region.
MATERIALS AND METHODS
Patients and Bacterial Isolates
This retrospective study was conducted in Ruijin Hospital,
an 1800-bed general university-affiliated hospital located in
Shanghai, with ∼1,15,000 patient visits per year. Patients with at
least one positive blood culture of K. pneumoniae from January
2012 through December 2015 were enrolled in the study. A total
of 254 episodes of K. pneumoniae bloodstream infections (66 in
2012, 62 in 2013, 64 in 2014, and 62 in 2015) were identified
during this period. Only the first positive blood culture was
reviewed and recorded. Eighty isolates were enrolled: twenty
isolates were selected from each year using the random number
generation function in Microsoft Office Excel 2010 (Microsoft
Corporation, Redmond, WA, USA). Isolates identification was
carried out using matrix-assisted laser desorption ionization-
time of flight mass spectrometer (bioMérieux, Marcy-l’Étoile,
France).
This study was approved by Ruijin Hospital Ethics Committee
(Shanghai Jiao Tong University School of Medicine). The Review
Board exempted request for informed consent because this
retrospective study only focused on the bacteria and did not have
impact on the patients.
Antimicrobial Susceptibility Tests
The antimicrobial susceptibility tests were determined by the
disk diffusion method according to the Clinical and Laboratory
Standards Institute [Clinical and Laboratory Standards Institute
(CLSI), 2015]. The antibiotics tested were ceftazidime,
ceftriaxone, cefepime, cefotaxime, cefuroxime, amikacin,
gentamicin, tobramycin, piperacillin, aztreonam, ciprofloxacin,
levofloxacin, ampicillin-sulbactam, piperacillin-tazobactam,
imipenem, meropenem, trimethoprim-sulfamethoxazole, and
cefoperazone-sulbactam. Pseudomonas aeruginosa ATCC 27853,
K. pneumoniae ATCC 700603, and E. coli ATCC 25922 were
used for quality control.
ESBL-Producing and
Carbapenemase-Producing Isolates
Screening and Confirmation
According to the CLSI criteria [Clinical and Laboratory
Standards Institute (CLSI), 2015], ceftazidime and cefotaxime
were used as screening tests for ESBLs. Ceftazidime, ceftazidime-
clavulanate, cefotaxime, and cefotaxime-clavulanate were used
as confirmatory test. Imipenem and meropenem were used
as screening for carbapenemase production. Detection of
carbapenemase genes was performed to confirm production of
carbapenemases.
Detection of Resistant Genes
Polymerase chain reaction (PCR) was performed to amplify
the resistant genes using previous primers (Du et al.,
2014; Zhao et al., 2016), including ESBL genes (blaTEM,
blaSHV, blaCTX−M−1, −2, −8, −9, −10, −25 group), blaVEB, blaGES,
blaOXA(−1, −2, −10 group),and blaPER) and carbapenemase genes
(blaVIM, blaIPM, blaKPC, blaGIM, blaSPM, blaSIM, blaOXA−48 group,
and blaNDM). Sample DNA was prepared by boiling the bacteria
at 100◦C for 15 min, and centrifugation at 3,000 g for 15 min.
The PCR conditions used were initial denaturation at 95◦C for
5 min, cyclic denaturation at 95◦C for 50 s, annealing at 55◦C
for 30 s, elongation at 72◦C for 1 min for 35 cylces and final
extension at 72◦C for 5 min. PCR products were examined by
electrophoresis in 1.5% agarose gel. Positive amplicons were
sequenced using ABI3730xl DNAAnalyzer by Sangon Biotech
(Shanghai, China) and aligned with subtypes of β-lactamase
genes by BLAST (http://blast.ncbi.nlm.nih.gov).
Multilocus Sequence Typing
Multilocus sequence typing (MLST) was carried out as described
previously (http://bigsdb.web.pasteur.fr/klebsiella/primers_used.
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html; Diancourt et al., 2005). Briefly, Seven hosekeeping genes
(gapA, infB, mdh, pgi, phoE, rpoB, and tonB) for K. pneumoniae
were amplified, sequenced, and analyzed. Alleles and STs
were determined according to the database (http://bigsdb.
web.pasteur.fr/perl/bigsdb/bigsdb.pl?db=pubmlst_klebsiella_
seqdef_public&page=profiles). STs that could not be found
in the database were submitted to the curator of the database
(klebsiellaMLST@pasteur.fr). eBURST version 3.0 software was
used to analyze the clustering of related STs. In this study,
isolates were grouped together if six of the seven alleles were
homologs.
Statistical Analysis
Data in this study were analyzed by SAS 8.2 (SAS Institute
Inc., Cary, NC, USA). Continuous variables were presented
as the mean ± SD or median and interquartile range. For
categorical variables, the chi-square test was used to compare the
disparity between different groups. P < 0.05 was considered to be
statistically significant.
RESULTS
Patient Data
From January 2012 to December 2015, there were more male
patients (182/254) than females (72/254). The age of patients
ranged from 1 to 91 years.Most of the cases (40/254) were derived
from the surgery. Fifty-eight males and 22 females were enrolled
and their median age was 61 years (range: 12–91 years). Most
patients were from the Department of General Surgery (17/80),
Transplantation (11/80), and Infectious Disease (9/80).
Antimicrobial Susceptibility Tests
Isolates bear high resistance to cefuroxime (56.3%), ampicillin-
sulbactam (52.5%), and piperacillin (52.5%), while there were
the least resistance to imipenem (17.5%), meropenem (18.8%),
and amikacin (20.0%). Of the 80 isolates, 22 isolates (27.5%)
were ESBL producers, and 14 (17.5%) were carbapenemase
producers. The resistant rates to most of the antibiotics in
ESBL producers were >60%, including cefuroxime (100.0%),
piperacillin (100.0%), cefotaxime (100.0%), ceftriaxone (100.0%),
ampicillin-sulbactam (86.4%), trimethoprim-sulfamethoxazole
(81.8%), gentamicin (77.3%), aztreonam (72.7%), ciprofloxacin
(63.6%), and cefepime (63.6%). The resistant rates to antibiotics
were significantly higher in ESBL producers than those in
non-producers except meropenem, levofloxacin, piperacillin-
tazobactam, imipenem, and amikacin. The carbapenemase
producers were resistant to all tested drugs except trimethoprim-
sulfamethoxazole, tobramycin, amikacin, and gentamicin.
Resistant rates to all antibiotics other than trimethoprim-
sulfamethoxazole were statistically different between the
carbapenemase producers and non-carbapenemase producers
(Table 1).
Characterization of Resistance Genes
In this study, 40.9% (9/22) blaTEM, 100.0% (22/22) blaSHV,
and 77.3% (17/22) blaCTX−M were identified in the 22 ESBL
producers. The dominan ESBL gene was blaCTX−M. The subtypes
of blaTEM were blaTEM−1(n = 8) and blaTEM−103(n = 1). The
main subtype of blaSHV was blaSHV−1 (n = 11), and the most
common subtype of blaCTX−M was blaCTX−M−14 (n = 7).
Other subtypes including blaSHV−33, blaSHV−36, blaSHV−11,
blaSHV−12, blaSHV−28, blaCTX−M−15, and blaCTX−M−65 were
TABLE 1 | Rates of antibiotics resistance in eighty K. pneumoniae bloodstream isolates.
Antibiotics Number of isolates (%) P Number of isolates (%) P
Total
(n = 80)
ESBL
(n = 22)
Non-ESBL
(n = 58)
Total
(n = 80)
Carbapenemase
(n = 12)
Non-carbapenemase
(N = 68)
Ceftazidime 25 (31.3) 11 (50.0) 14 (24.1) 0.0259 25 (31.3) 12 (100.0) 13 (19.1) <0.0001
Ceftriaxone 38 (47.5) 22 (100.0) 16 (27.6) <0.0001 38 (47.5) 12 (100.0) 26 (38.2) <0.0001
Cefepime 29 (36.3) 14 (63.6) 15 (25.9) 0.0017 29 (36.3) 12 (100.0) 17 (25.0) <0.0001
Cefotaxime 38 (47.5) 22 (100.0) 16 (27.6) <0.0001 38 (47.5) 12 (100.0) 26 (38.2) <0.0001
Cefuroxime 45 (56.3) 22 (100.0) 23 (39.7) <0.0001 45 (56.3) 12 (100.0) 33 (48.5) 0.0009
Amikacin 16 (20.0) 4 (18.2) 12 (20.7) 1.0000 16 (20.0) 10 (83.3) 6 (8.8) <0.0001
Gentamicin 33 (41.3) 17 (77.3) 16 (27.6) <0.0001 33 (41.3) 11 (91.7) 22 (32.4) 0.0004
Tobramycin 26 (32.5) 12 (54.5) 14 (24.1) 0.0095 26 (32.5) 11 (91.7) 15 (22.1) <0.0001
Piperacillin 42 (52.5) 22 (100.0) 20 (34.5) <0.0001 42 (52.5) 12 (100.0) 30 (44.1) 0.0004
Aztreonam 31 (38.8) 16 (72.7) 15 (25.9) 0.0001 31 (38.8) 12 (100.0) 19 (27.9) <0.0001
Ciprofloxacin 33 (41.3) 14 (63.6) 19 (32.8) 0.0122 33 (41.3) 12 (100.0) 21 (30.9) <0.0001
Levofloxacin 26 (32.5) 9 (40.9) 17 (29.3) 0.3227 26 (32.5) 12 (100.0) 14 (20.6) <0.0001
Ampicillin-sulbactam 42 (52.5) 19 (86.4) 23 (39.7) 0.0002 42 (52.5) 12 (100.0) 30 (44.1) 0.0004
Piperacillin-tazobactam 20 (25.0) 6 (27.3) 14 (24.1) 0.7725 20 (25.0) 12 (100.0) 8 (11.8) <0.0001
Imipenem 14 (17.5) 3 (13.6) 11 (19.0) 0.8176 14 (17.5) 12 (100.0) 2 (2.9) <0.0001
Meropenem 15 (18.8) 2 (9.1) 13 (22.4) 0.2972 15 (18.8) 12 (100.0) 3 (4.4) <0.0001
Trimethoprim-sulfamethoxazole 38 (47.5) 18 (81.8) 20 (34.5) 0.0002 38 (47.5) 7 (58.3) 31 (45.6) 0.4150
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also found. Five of the 22 isolates (22.7%) only harbored
blaSHV. While the other 17 isolates additionally harbored
one or two ESBL genes, including blaSHV along with
blaCTX−M(8/22), and blaSHV along with blaCTX−M and blaTEM
(9/22) (Table 2). No blaCTX−M(−2, −8, −10, −25 group), blaVEB,
blaGES, blaOXA(−1, −2, −10 group), or blaPERgenes were found.
The blaKPC−2 gene was detected in 92.9% (13/14)
carbapenemase producers and blaNDM−5was found in another
isolate. No other carbapenemase genes were detected.
ST and Clonal Complexes
Forty-seven STs among 80 K. pneumoniae isolates, including
three new STs (ST2247, ST2248, and ST2249) were identified.
The most prevalent ST in K. pneumoniae isolates was ST11
(n = 14, 17.5%), followed by ST15 (n = 7, 8.7%), and ST29
(n = 4, 5.0%) (Table 3). eBURST indicated that these 47 STs
could be clustered into one clonal complex, four groups, and
35 singletons (Figure 1). Notably, ESBL producers were mostly
ST15 (5/22, 22.7%), ST11 (3/22, 13.6%), and ST628 (3/22, 13.6%),
while all carbapenemase producers belonged to ST11 except the
blaNDM−5-positive one (ST1).
DISCUSSION
Local epidemiologic data on prevalence of specific clones of
K. pneumoniae bloodstream infection were indispensible to
develop clinical treatment regimen and evaluate outcomes of
different therapeutic strategy (Pai et al., 2004; Marra et al., 2006;
Neuner et al., 2011; Harris et al., 2015). However, there were
limited data on antibiotic resistance, resistant genes and STs of
K. pneumoniae bloodstream isolates in Shanghai. In our pilot
study conducted in 2012, we found that K. pneumoniae was the
second frequent gram negative bacillus from blood cultures in
our hospital, representing 14.3% of all the isolates (Zhao et al.,
TABLE 2 | Resistant genes in ESBL-producing or
carbapenemase-producing isolates from K. pneumoniae bloodstream
isolates during 2012–2015.
Genes Number of isolates (%)
Total 2012 2013 2014 2015
ESBL 22 (27.5) 3 (15.0) 7 (35.0) 7 (35.0) 5 (25.0)
blaTEM−1 8 (36.4) 1 (33.3) 2 (28.6) 2 (28.6) 3 (60.0)
blaTEM−103 1 (4.5) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0)
blaSHV−1 11 (50.0) 2 (66.7) 5 (71.4) 1 (14.3) 3 (60.0)
blaSHV−33 1 (4.5) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0)
blaSHV−36 2 (9.1) 0 (0.0) 2 (28.6) 0 (0.0) 0 (0.0)
blaSHV−11 3 (13.6) 0 (0.0) 0 (0.0) 2 (28.6) 1 (20.0)
blaSHV−12 4 (18.2) 0 (0.0) 0 (0.0) 4 (57.1) 0 (0.0)
blaSHV−28 1 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0)
blaCTX−M−15 6 (27.3) 1 (33.3) 2 (28.6) 2 (28.6) 1 (20.0)
blaCTX−M−14 7 (31.8) 0 (0.0) 4 (57.1) 1 (14.3) 2 (40.0)
blaCTX−M−65 4 (18.2) 2 (66.7) 0 (0.0) 1 (14.3) 1 (20.0)
Carbapenemase 12 (15.0) 0 (0.0) 1 (5.0) 5 (25.0) 6 (30.0)
blaKPC−2 12 (100.0) 0 (0.0) 1 (100.0) 5 (100.0) 6 (100.0)
2014). In current study, we have extended our research through
2015 to acquire more comprehensive molecular epidemiologic
data.
K. pneumoniae bloodstream isolates in the study showed
threatened resistance to the most of routine antibiotics and only
meropenem, imipenem, amikacin, and piperacillin-tazobactam
had relative low resistant rates (<30%) which made them better
candidates for empiric therapy of K. pneumoniae bloodstream
infections. However, prudent and rational uses of antibiotics
based on the results of antimicrobial susceptibility tests are still
essential to the success of treatment. Notably, the resistant rates
to meropenem, imipenem, amikacin, cefepime, and ciprofloxacin
determined in this study were much higher than what were
found in the surveillance of 2011–2012 in China (Li et al.,
2014). This dynamic change of the pattern of drug resistance
warrant active ongoing surveillance on antibiotic resistance and
consistent prevention and control of K. pneumoniae.
The proportion of ESBL-producing K. pneumoniae (27.5%)
in this study was lower than that in Italy (32.6%), America
(51.8%), Korea (52.9%), and Russia (60.8%) (Kim et al., 2002;
Edelstein et al., 2003; Marra et al., 2006; Tumbarello et al., 2006),
but the multidrug-resistant phenotype, and the dominate ESBL
enzyme (CTX-M) of ESBL producers were similar (Edelstein
et al., 2003). Typing of ESBL producers revealed a high level of
genetic diversity, with ST15 (22.7%, 5/22) and ST11 (13.6%, 3/22)
as themost common STs. ST15K. pneumoniae has been identified
in both animals and humans in several countries. Although it
was not yet a dominant clone in our study, ST15 K. pneumoniae
had achieved a highly successful clonal spread in some countries,
such as Bulgaria, Portugal, and Thailand (Netikul et al., 2014;
Rodrigues et al., 2014; Markovska et al., 2015), and we should
be cautious about its high potential of becoming a major clone
associated with ESBL producers in Shanghai in future. Isolates
belonged to ST11 were isolated from different departments, in
different years with different antibiotic resistance profiles. This
suggested no clonal dissemination in the region.
Different from previous studies where no carbapenemase-
producing E. coli bloodstream isolate was found (Zhao et al.,
2015; Wang et al., 2016), the carbapenemase-producing K.
pneumoniae accounted for 17.5% in our hospital, and they, as
reported elsewhere (David et al., 2013; Du et al., 2014), also
showed extremely high resistant rates to major antibiotics except
aminoglycosides and trimethoprim-sulfamethoxazole. Molecular
analysis suggested 92.9% of the carbapenemase producers were
harbored with blaKPC−2, and belonged to ST11, confirming
that ST11 was associated with KPC. Unlike the widespread of
KPC-producing ST258 K. pneumoniae in Europe, the dominant
ST of KPC-producing K. pneumoniae was ST11 in China
(Dautzenberg et al., 2016). Also, One ST1 carbapenemase
producers carried blaNDM−5 was found in this study. NDM-
5, which mostly found in E. coli, was firstly reported in K.
pneumoniae in Shanghai. Taken together, our data indicated
the KPC-producing ST11 K. pneumoniae isolate was a high-
risk clone in our hospital, and should be taken as the major
consideration when developing strategy to control resistant
isolates dissemination. NDM, along with KPC, VIM, and OXA-
48, were four major carbapenemases detected in K. pneumoniae.
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TABLE 3 | Antibiotic resistance profiles and genotypes in MLST of eighty K. pneumoniae isolates from bloodstream infections.
ST Antibiotic resistance profiles Resistance determinants Number of isolates
ST1 CAZ-CRO-FEP-CTX-CXM-TOB-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM-SXT – 1
ST2 - – 1
ST6 CAZ-CRO-FEP-CTX-CXM-PRL-ATM-SAM-TZP SHV-1 1
ST11 CAZ-CRO-CTX-CXM-TOB-PRL-ATM-CIP-LEV-SAM-SXT SHV-11 1
CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM KPC-2 3
CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM TEM-1, SHV-11, CTX-M-14, KPC-2 1
CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM-SXT KPC-2 6
CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-LEV-SAM-TZP-MEM – 1
CAZ-CRO-FEP-CTX-CXM-CN-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM-SXT KPC-2 1
CAZ-CRO-FEP-CTX-CXM-CN-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM-SXT SHV-12, CTX-M-14, KPC-2 1
CAZ-CRO-FEP-CTX-CXM-TOB-PRL-ATM-CIP-LEV-SAM-TZP-IPM-MEM
ST15 CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-LEV-SAM-IPM-SXT SHV-1, CTX-M-14 1
CAZ-CRO-FEP-CTX-CXM-CN-TOB-PRL-ATM-CIP-LEV-SAM-TZP-SXT SHV-12 1
CAZ-CRO-FEP-CTX-CXM-CN-TOB-PRL-ATM-CIP-SAM-SXT TEM-1, SHV-1, CTX-M-15 1
CAZ-CRO-FEP-CTX-CXM-CN-TOB-PRL-ATM-CIP-SAM-TZP-SXT TEM-1, SHV-12, CTX-M-15 1
CIP-LEV-SAM-SXT – 2
CRO-CTX-CXM-PRL-ATM-CIP-LEV-SAM-SXT SHV-1 1
ST23 – – 3
ST26 CRO-CTX-CXM-PRL-SAM-SXT SHV-28 1
ST29 – – 2
CXM-SAM – 2
ST35 CTX-CXM-CN-PRL-SXT – 1
CAZ-CRO-FEP-CTX-CXM-CN-TOB-PRL-ATM-CIP-SAM-SXT TEM-1, SHV-33, CTX-M-15 1
ST37 CRO-CXM-CN-PRL-SXT – 1
CAZ-CXM-TOB-PRL-CIP-LEV-SAM-SXT – 1
ST45 – – 1
ST60 – – 1
ST65 – – 1
ST86 CXM-SAM – 1
CXM-SXT – 1
ST107 CRO-FEP-CTX-CXM-CN-PRL-ATM-SAM-SXT SHV-36, CTX-M-14 2
ST218 – – 1
ST231 CRO-FEP-CTX-CXM-CN-PRL-ATM-CIP-LEV-SAM-SXT TEM-1, SHV-1, CTX-M-65 1
ST245 – – 1
ST252 – – 1
ST290 CRO-CTX-CXM-CN-PRL-SAM-SXT TEM-103, SHV-1, CTX-M-65 1
ST307 CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-LEV-SAM-TZP-SXT TEM-1, SHV-1, CTX-M-15 1
ST340 CRO-FEP-CTX-CXM-PRL-ATM-CIP-LEV-SAM-TZP-MEM-SXT – 1
ST347 – – 1
ST367 – – 1
ST374 – – 1
ST380 – – 1
ST397 CRO-FEP-CTX-CXM-CN-TOB-PRL-ATM-CIP-SAM-SXT TEM-1, SHV-1, CTX-M-15 1
ST412 – – 1
ST485 – – 2
ST628 CRO-CTX-CXM-CN-PRL-SXT SHV-1, CTX-M-14 1
CRO-CTX-CXM-CN-PRL-CIP-LEV-SAM-SXT SHV-1, CTX-M-14 1
CRO-CTX-CXM-CN-PRL-SXT SHV-1, CTX-M-65 1
ST629 CRO-CTX-CXM-CN-TOB-PRL SHV-11, CTX-M-65 1
ST685 CIP-LEV-SXT – 1
ST788 – – 1
(Continued)
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TABLE 3 | Continued
ST Antibiotic resistance profiles Resistance determinants Number of isolates
ST948 – – 1
ST1023 CXM-AK-CN-TOB-PRL-CIP-SAM-SXT – 1
ST1118 SXT – 1
ST1333 – – 2
ST1440 – – 1
ST1465 CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-CIP-SAM-SXT TEM-1, SHV-12, CTX-M-15 1
ST1545 – – 2
ST1712 CRO-FEP-CTX-CXM-CN-PRL-ATM-CIP-SAM-SXT – 1
ST1765 CAZ-CRO-FEP-CTX-CXM-AK-CN-TOB-PRL-ATM-SAM-TZP – 1
ST1779 PRL-SAM – 1
ST1887 SXT – 1
ST2247 – – 1
ST2248 – – 1
ST2249 – – 1
CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; CTX, cefotaxime; CXM, cefuroxime; AK, amikacin; CN, gentamicin; TOB, tobramycin; PRL, piperacillin; ATM, aztreonam; CIP,
ciprofloxacin; LEV, levofloxacin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; IPM, imipenem; MEM, meropenem; SCF, cefoperazone-sulbactam; SXT, trimethoprim-
sulfamethoxazole.
FIGURE 1 | Clonal groupings among K. pneumoniae bloodstream isolates. There were 35 singletons, four groups (group 1: ST37, ST1779; group 2: ST11,
ST340; group 3: ST347, ST1023; group 4: ST485, ST45) and one clonal complexes (ST218, ST23, ST2248) with ST23 as the putative founder. One blob represented
one ST and the size reflected the number of isolates belonging to it.
The most common type of NDM found was NDM-1. NDM-5, an
emerging carbapenemase in K. pneumoniae, should attract our
attention.
Our study described the phenotypic and molecular
properties of K. pneumoniae bloodstream isolates in
Shanghai for the first time. This study also suggested ST11
K. pneumoniae harbored blaKPC−2 had absolute predominance
in carbapenemase producers, and NDM-5 was an emerging
carbapenemase. Although our conclusion based on a single
hospital cannot be directly extrapolated to the whole area,
it provides the stepstone for the future expanded research
associated with multicenter and further resistant mechanism
surveillance to prevent further possible dissemination in this
region.
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